Format

Send to

Choose Destination
Semin Oncol. 2002 Aug;29(4):389-99.

Adjuvant therapy for patients with high-risk malignant melanoma.

Author information

1
San Diego Cancer Research Institute, and San Diego Melanoma Research Program, Vista, CA, USA.

Abstract

The role of adjuvant therapy in the treatment of patients with high-risk malignant melanoma remains an area of intense investigation. The initial enthusiasm for high-dose interferon has been tempered by the results of more recent studies that allow for conflicting interpretations. Vaccine therapy trials have failed to clearly demonstrate a survival benefit, although several trials are currently ongoing. Recent studies of the role of chemotherapy suggest there may be combinations that have a survival benefit which deserve further study. This article will address patient selection and staging workup, and review options for treatment.

PMID:
12170442
DOI:
10.1053/sonc.2002.34118
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center